BioVaxys Technology Corp. (CSE:BIOV)
Canada flag Canada · Delayed Price · Currency is CAD
0.0400
0.00 (0.00%)
Apr 25, 2025, 3:59 PM EDT

BioVaxys Technology Company Description

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics.

The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases.

It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, a formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy.

In addition, the company develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health’s proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine.

Further, the company operates HapTenix Platform, a vaccine platform based on the established immunological concept that modifies surface proteins with haptens and T-Cell Antigen Discovery Program.

It has agreement with AP Visionaries, Inc. to develop a proprietary DPX formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies triggered by exposure to peanut/tree nuts or eggs.

BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.

BioVaxys Technology Corp.
Country Canada
Industry Biotechnology
Sector Healthcare
CEO James Passin

Contact Details

Address:
146 Thirtieth Street
Etobicoke, British Columbia M8W 3D4
Canada
Phone 740-358-0555
Website biovaxys.com

Stock Details

Ticker Symbol BIOV
Exchange Canadian Securities Exchange
Fiscal Year November - October
Reporting Currency CAD
ISIN Number CA09076M1014
SIC Code 2834

Key Executives

Name Position
James Christopher Passin Co-Founder, Chief Executive Officer, and Director
Kenneth E. Kovan Co-Founder, President and Chief Operating Officer